Needham Downgrades Aeglea BioTherapeutics to Hold
Needham analyst Gil Blum downgrades Aeglea BioTherapeutics (NASDAQ:AGLE) from Buy to Hold.
HC Wainwright & Co. Downgrades Aeglea BioTherapeutics to Neutral, Lowers Price Target to $1
HC Wainwright & Co. analyst Edward White downgrades Aeglea BioTherapeutics (NASDAQ:AGLE) from Buy to Neutral and lowers the price target from $17 to $1.
Mid-Afternoon Market Update: Dow Surges Over 200 Points; Immunic Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday.
Mid-Day Market Update: U.S. Stocks Turn Positive; Nasdaq Jumps 150 Points
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining 150 points on Thursday.
Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) announced the U.S. Food and Drug Administration (FDA) has refused to accept the company’s Biologics License Application (BLA) with a Refusal to File (RTF) letter.
Aeglea BioTherapeutics Earnings Perspective: Return On Capital Employed
Aeglea BioTherapeutics (NASDAQ:AGLE) brought in sales totaling $1.36 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 19.51%, resulting in a loss of $24.44 million.
Piper Sandler Maintains Overweight on Aeglea BioTherapeutics, Lowers Price Target to $4
Piper Sandler analyst Edward Tenthoff maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Overweight and lowers the price target from $7 to $4.
Aeglea BioTherapeutics Says Entered Into Sales Agreement With JonesTrading, Dated May 20, 2022, Relating To Sale Of Up To $60M Shares Of Co’s Common Stock
On May 20, 2022, Aeglea BioTherapeutics, Inc. (the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Offering Agreement”) with JonesTrading Institutional Services LLC,